PhRMA submission to 2020 National Trade Estimate Report: Urgent action required to protect U.S. biopharmaceutical innovation
By Douglas Petersen | November 8, 2019
International trade policy plays a critical role in ensuring that the U.S. biopharmaceutical industry can continue to develop and provide both American and international patients with access to...
Read More
IP Explained: By the Numbers: How reliable IP protections promote a strong U.S. economy
By Tom Wilbur | November 4, 2019
The U.S. biopharmaceutical industry depends on predictable and reliable intellectual property (IP) protections, including patents, to maintain its role as the global leader in biopharmaceutical...
Read More
What they are saying: Negative impact of Pelosi’s plan on biopharmaceutical innovation
By Tom Wilbur | October 31, 2019
Recently, House Speaker Nancy Pelosi unveiled a radical drug pricing plan, H.R. 3, that would be the wrong approach for patients, the U.S. health care system and the economy.
Read More
Pelosi’s radical plan leaves lung cancer patients behind
By Tom Wilbur | October 23, 2019
Lung cancer is the second most common form of cancer in men and women and the leading cause of cancer-related deaths in the United States. In 2019 alone, there will be an estimated 228,000 new...
Read More
Pelosi’s radical plan would leave Alzheimer’s patients behind
By Tom Wilbur | October 16, 2019
Last month, House Speaker Nancy Pelosi unveiled a radical drug pricing plan, H.R. 3, that could jeopardize the development of innovative treatments for some of the most challenging diseases and...
Read More
Event tomorrow: Maintaining America’s leadership in access and innovation
By Andrew Powaleny | October 16, 2019
Each year, biopharmaceutical companies invest nearly $100 billion in the discovery of new treatments and cures. Despite a challenging research and development (R&D) process, consistently high...
Read More
What they are saying: Broad opposition to Pelosi’s radical drug pricing plan
By Tom Wilbur | October 10, 2019
Recently, House Speaker Nancy Pelosi unveiled a radical drug pricing plan that would be the wrong approach for patients, the U.S. health care system, economy, and American innovation. An...
Read More
By the Numbers: Pelosi’s radical plan puts America’s economy and jobs at risk
By Tom Wilbur | September 26, 2019
We already know that the radical drug pricing plan unveiled last week by House Speaker Nancy Pelosi is the wrong approach for patients, the U.S. health care system, and American innovation. But...
Read More
Guest Post: Following my stroke, having access to ground-breaking medical innovation has never been more important
By Guest Contributor | September 4, 2019
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...
Read More
New Report: Advanced manufacturing powering innovative biopharmaceuticals
By Tim McClung | May 10, 2019
The science-based advanced manufacturing infrastructure of the biopharmaceutical industry is critical to fueling the innovation necessary to bring new treatments and cures to patients. With a...
Read More
Medicare Monday (100)
340B Spotlight (43)
Cost & Consequence (0)
